Holen Sie sich die Stockscreener-App
0.82
2.50%
0.02
Schlusskurs vom Vortag:
$0.80
Offen:
$0.75
24-Stunden-Volumen:
4,136
Relative Volume:
10.85
Marktkapitalisierung:
$N/A
Einnahmen:
$257.55M
Nettoeinkommen (Verlust:
$11.95M
KGV:
0.9011
EPS:
0.91
Netto-Cashflow:
$-9.39M
1W Leistung:
+16.07%
1M Leistung:
-76.15%
6M Leistung:
-81.21%
1J Leistung:
-93.26%
1-Tages-Spanne:
$0.75
$0.82
1-Wochen-Bereich:
$0.66
$0.82
52-Wochen-Spanne:
$0.66
$0.82
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Vergleichen Sie EGRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
0.82 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
|
ZTS
Zoetis Inc
|
171.14 | 77.44B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.555 | 43.22B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.54 | 42.94B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.82 | 18.94B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
127.15 | 13.51B | 612.78M | -86.37M | -62.91M | -0.87 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2018-11-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-31 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-03-21 | Bestätigt | Mizuho | Underperform |
| 2017-11-09 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-06 | Bestätigt | Mizuho | Underperform |
| 2017-07-27 | Bestätigt | Mizuho | Underperform |
| 2017-07-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-05-09 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-01-09 | Herabstufung | Mizuho | Neutral → Underperform |
| 2016-11-16 | Herabstufung | Mizuho | Buy → Neutral |
| 2016-11-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2016-11-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-26 | Bestätigt | Mizuho | Buy |
| 2016-08-16 | Bestätigt | Mizuho | Neutral |
| 2016-06-20 | Herabstufung | Mizuho | Buy → Neutral |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-03-18 | Bestätigt | Mizuho | Buy |
| 2016-02-26 | Bestätigt | Mizuho | Buy |
| 2015-12-09 | Eingeleitet | Mizuho | Buy |
| 2015-07-29 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Eagle Pharmaceuticals Inc Aktie (EGRX) Neueste Nachrichten
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. Enters Third Amended and Restated Credit Agreement - Marketscreener.com
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - Defense World
Jane Street Group LLC Makes New Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09% - MSN
Antiemetics Drugs Market Size & Share Report, 2024 – 2032 - Global Market Insights
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Last Week's Biggest Stock Movers: Eagle, Noodles & Co. - AOL
Eagle Pharmaceuticals Enters Into Settlement Agreement With Dr. Reddy's Laboratories on Leukemia Drug - Marketscreener.com
Eagle Pharmaceuticals : to Present at Jefferies Virtual Healthcare Conference 2021 - Marketscreener.com
Eagle Pharmaceuticals Amends Rights Agreement with Equiniti Trust Company - Defense World
Eagle Pharmaceuticals amends rights agreement - Investing.com
Eagle Pharmaceuticals amends rights agreement By Investing.com - Investing.com Nigeria
Eagle Pharmaceuticals Dismisses Ernst & Young LLP as Independent Registered Public Accounting Firm - Defense World
Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal - Investing.com
Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceutica - GuruFocus.com
Eagle Pharma Founder Sues Company to Recoup Cost of SEC Investigation - Law.com
Ex-Pharma CEO Demands Legal Fees For SEC Probe - Law360
Eagle Pharmaceuticals names Christopher Krawtschuk as CFO - MSN
Eagle Pharmaceuticals to Delist from Nasdaq By Investing.com - Investing.com Australia
Eagle Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
Eagle Pharmaceuticals to Delist from Nasdaq - Investing.com India
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration - The Manila Times
Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension | EGRX Stock News - StockTitan
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Citigroup Inc's Strategic Reduction in Eagle Pharmaceuticals Inc Shares - GuruFocus.com
Creative Planning Makes New $59,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerWOODCLIFF LAKE, N.J. — November 12, 2024 — Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) recently announced the appointment of Christopher Krawtschuk as the Chief - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - The Manila Times
Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Some Major Key Players In The Heparin-Induced Thrombocytopenia (HIT) Treatment Market: - InsightAce Analytic
Nantahala Capital Management Reduces Stake in Eagle Pharmaceuticals - GuruFocus.com
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’S Disease in Collaboration with University of Pennsylvania - Marketscreener.com
Eagle Pharmaceuticals Adopts Stockholder Rights Plan to Protect Shareholders’ Interests - Defense World
Union Square Park Capital Management, LLC Increases Stake in Eagle Pharmaceuticals Inc - GuruFocus.com
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan - The Manila Times
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle - GlobeNewswire
Pemetrexed Market Is Booming Worldwide 2024-2031 | Stada - openPR
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - ForexTV.com
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire Inc.
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire
Finanzdaten der Eagle Pharmaceuticals Inc-Aktie (EGRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
3.97%
Kapitalisierung:
|
Volumen (24h):